Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose

BioMetals

Volumn 24, Issue 4, 2011, Pages 603-613

  Pai, Amy Barton ^a   Conner, Todd ^b   McQuade, Charles R ^c   Olp, Jonathan ^c   Hicks, Paul ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b VA Medical Center   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Hemodialysis; Intravenous iron; Oxidative stress

Indexed keywords

FERRIC HYDROXIDE SUCROSE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON DEXTRAN; ISOPROSTANE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ADMINISTRATION ROUTE; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; LIPID PEROXIDATION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR WEIGHT; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION;

ADULT; CROSS-OVER STUDIES; CYTOKINES; F2-ISOPROSTANES; FEMALE; FERRIC COMPOUNDS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; IRON-DEXTRAN COMPLEX; LIPID PEROXIDATION; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MOLECULAR WEIGHT; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS;

EID: 79960102454     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-011-9409-6     Document Type: Article

References (36)

1. RM Adibhatla JF Hatcher 2010 Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities Antioxid Redox Signal 12 1 125 169 19624272 10.1089/ars.2009.2668 1:CAS:528:DC%2BC3cXhsFejt7k%3D
2. VS Balakrishnan, et al. 2009 Physiochemical properties of ferumoxytol, a new intravenous iron preparation Eur J Clin Invest 39 1 8 10.1111/j.1365-2362. 2009.02130.x
3. A Besarab WK Bolton JK Browne, et al. 1998 The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 584 590 9718377 10.1056/NEJM199808273390903 1:CAS:528:DyaK1cXlvVyrtr8%3D (Pubitemid 28385655)
4. W Breuer ZI Cabantchik 2001 A fluorescence-based one-step assay for serum non-transferrin bound iron Anal Biochem 299 194 202 11730343 10.1006/abio.2001.5378 1:CAS:528:DC%2BD3MXoslSktbk%3D (Pubitemid 34053410)
5. Centers for Medicare and Medicaid Services, Conditions for Coverage, ESRD Conditions Final Rule, April 15, 2008. http://www.cms.gov/CFCsAndCoPs/13-ESRD. asp. Cited 9 Aug 2010
6. BG Danielson 2004 Structure, chemistry, and pharmacokinetics of intravenous iron agents J Am Soc Nephrol 15 Suppl 2 S93 S98 15585603
7. WP den Elzen JG van Manen EW Boeschoten, et al. 2006 The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis Nephrol Dial Transplant 21 6 1588 1595 10.1093/ndt/gfk092 (Pubitemid 43834640)
8. TB Drüeke F Locatelli N Clyne, et al. 2006 Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2071 2084 17108342 10.1056/NEJMoa062276 (Pubitemid 44749316)
9. HI Feldman M Joffe B Robinson, et al. 2004 Administration of parenteral iron and mortality among hemodialysis patients J Am Soc Nephrol 15 6 1623 1632 15153574 10.1097/01.ASN.0000128009.69594.BE 1:CAS:528:DC%2BD2cXktVWiu7s%3D (Pubitemid 38679688)
10. Fleming MD (2008) The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 151-158
11. N Garcia-Fernandez A Echeverria A Sanchez-Ibarrola, et al. 2010 Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis Nephrology (Carlton) 15 2 178 183 10.1111/j.1440-1797.2009.01174.x 1:CAS:528:DC%2BC3cXltl2qt7w%3D
12. S Granata G Zaza S Simone, et al. 2009 Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease BMC Genomics 10 388 19698090 10.1186/1471-2164-10-388
13. PA Henderson RS Hillman 1969 Characteristics of iron dextran utilization in man Blood 34 3 357 375 5804025 1:CAS:528:DyaF1MXlt1aht74%3D
14. J Himmelfarb P Stenvinkel TA Ikizler, et al. 2002 The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 5 1524 1538 12371953 10.1046/j.1523-1755.2002.00600.x 1:CAS:528:DC%2BD38Xos1eksb0%3D (Pubitemid 35286260)
15. AC Johnson K Becker RA Zager 2010 Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury Am J Physiol Renal Physiol 299 2 F426 F435 20504881 10.1152/ajprenal.00248.2010 1:CAS:528:DC%2BC3cXhtVOgsrzE
16. K Kalantar-Zadeh DL Regidor CJ McAllister, et al. 2005 Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol 16 10 3070 3080 16033854 10.1681/ASN.2005040423 1:CAS:528: DC%2BD2MXhtFegtLbO (Pubitemid 44743505)
17. KDOQI 2006 Clinical practice guidelines, clinical practice recommendations for anemia in chronic kidney disease Am J Kidney Dis 47 S11 S145 10.1053/j.ajkd.2006.03.010
18. KL Kuo SC Hung YH Wei, et al. 2008 Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients J Am Soc Nephrol 19 9 1817 1826 18495964 10.1681/ASN.2007101084 1:CAS:528:DC%2BD1cXhtFensrnP
19. PS Lim YH Wei YL Yu, et al. 1999 Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy Nephrol Dial Transplant 14 268 2680 10.1093/ndt/14.11.2680
20. HJ Manley DW Grabe 2004 Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in vitro study BMC Nephrol 5 1 1 7 14718064 10.1186/1471-2369-5-1
21. JD Morrow KE Hill RF Burk, et al. 1990 A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc Natl Acad Sci USA 87 23 938 10.1073/pnas.87.23.9383
22. AB Pai A Harford AV Boyd, et al. 2007 Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose Pharmacotherapy 27 343 350 17316146 10.1592/phco.27.3.343 1:CAS:528:DC%2BD2sXjsVKks7s%3D (Pubitemid 46327902)
23. AB Pai JC Nielson A Kausz, et al. 2010 Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects Clin Pharmacol Ther 88 2 237 242 20592725 10.1038/clpt.2010.80 1:CAS:528:DC%2BC3cXptVCks7g%3D
24. V Panichi U Maggiore D Taccola 2004 Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients Nephrol Dial Transplant 19 5 1154 1160 14993508 10.1093/ndt/gfh052 1:CAS:528:DC%2BD2cXjsVertrg%3D (Pubitemid 38628135)
25. MA Pfeffer EA Burdmann CY Chen, et al. 2009 A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2019 2032 19880844 10.1056/NEJMoa0907845
26. ® (2009) Watson Pharma, Inc. Morristown, NJ, September 2009
27. DS Raj MA Boivin EA Dominic, et al. 2007 Haemodialysis induces mitochondrial dysfunction and apoptosis Eur J Clin Invest 37 12 971 977 18036031 10.1111/j.1365-2362.2007.01886.x 1:CAS:528:DC%2BD1cXlslCksA%3D%3D (Pubitemid 350151187)
28. PA Seligman NV Dahl J Strobos, et al. 2004 Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects Pharmacotherapy 24 5 574 583 15162891 10.1592/phco.24.6.574.34750 1:CAS:528:DC%2BD2cXlvVelt70%3D (Pubitemid 38585951)
29. M Shvartsman R Kikkeri A Shanzer, et al. 2007 Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications Am J Physiol Cell Physiol 293 4 C1383 C1394 17670894 10.1152/ajpcell.00054.2007 1:CAS:528:DC%2BD2sXht1WltbvJ (Pubitemid 47556747)
30. AK Singh L Szczech KL Tang, et al. 2006 Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2085 2098 17108343 10.1056/NEJMoa065485 1:CAS:528:DC%2BD28Xht1Wqt7fN (Pubitemid 44749317)
31. JE Toblli G Cao L Olivieri, et al. 2010 Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds Nephrol Dial Transplant 25 11 3631 3640 20488820 10.1093/ndt/gfq260 1:CAS:528:DC%2BC3cXhtlClurbN
32. A Van Campenhout C Van Campenhout A Lagrou, et al. 2008 Iron-induced oxidative stress in hemodialysis patients: a pilot study on the impact of diabetes Biometals 21 159 170 17585373 10.1007/s10534-007-9104-9 1:CAS:528:DC%2BD1cXjsFajsbs%3D (Pubitemid 351421984)
33. D Van Wyck J Anderson K Johnson 2004 Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol Dial Transplant 19 3 561 565 14767009 10.1093/ndt/gfg579 (Pubitemid 38263113)
34. RA Zager 2006 Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease Clin J Am Soc Nephrol 1 Suppl 1 S24 S31 17699373 10.2215/CJN.01410406 1:CAS:528:DC%2BD28XhtVOnsbvM
35. RA Zager ACM Johnson SY Hanson, et al. 2002 Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury Am J Kidney Dis 40 1 90 103 12087566 10.1053/ajkd.2002.33917 1:CAS:528:DC%2BD38Xlsl2itLg%3D (Pubitemid 34701216)
36. J Zaritsky B Young HJ Wang, et al. 2009 Hepcidin-a potential novel biomarker for iron status in chronic kidney disease Clin J Am Soc Nephrol 4 6 1051 1056 19406957 10.2215/CJN.05931108 1:CAS:528:DC%2BD1MXnsF2rtbk%3D